movement disorders:纹状体的血脑屏障开放,或有助于预防帕金森痴呆

2022-07-11 Freeman MedSci原创

FUS介导的纹状体BBB开放是可行和安全的

血脑屏障(BBB)在很大程度上限制了潜在的治疗分子进入大脑的机会。近年来,聚焦超声(FUS)和静脉注射微泡的组合已被证明可以在特定的大脑目标处短暂地破坏BBB。



图1: 论文封面图

在阿尔茨海默病(AD)、肌萎缩侧索硬化症和帕金森病(PD)患者中,已经开展了一些试点临床试验,分别在前额白质、海马体、初级运动皮层和顶枕部连接处进行BBB开放。这些报告证明了这种方法的可行性和安全性,包括在这些常见的神经退行性疾病中重复FUS介导的BBB开放达三次。

帕金森病的特点是进行性的纹状体(尾状核)多巴胺能神经支配,与运动性发病的基本特征有关。因此,黑质体投射可以说是在帕金森病早期提供神经恢复性疗法的主要目标。然而,众所周知,纹状体对各种代谢紊乱和物理损伤相当脆弱。因此,在PD中定义BBB纹状体开放本身的安全性和影响是迈向该方法可能的治疗应用的第一步。

相反,虽然BBB的开放主要是为了促进大脑接触假定的治疗方法,但它与实验和AD患者8的淀粉样细胞外沉积的减少有关。在小鼠中,这种针对AD病理学的效果似乎通过同时提供针对β-淀粉样蛋白和tau的抗体而得到加强。

有趣的是,路易体病理和AD病理在PD与痴呆(PDD)中都很突出,而且,PDD患者的纹状体β-淀粉样蛋白积累比没有痴呆的患者更常见。

藉此,马德里Fundacion Hospitales de Madrid的José A. Pineda-Pardo等人,假设:纹状体BBB开放是可行的、可逆的、安全的和良好的容忍性。另外,关于安全性,他们测试了反复暴露和双侧干预是否与多巴胺能的进一步丧失有关。最后,研究纹状体BBB开放是否会减少纹状体β-淀粉样蛋白的负担,正如在大脑皮层和海马区所描述的那样。

图2:论文结果图


共有7名患有认知障碍的PD患者接受了后壳核BBB开放治疗。分两个疗程进行,间隔时间为2至4周,其中第二个疗程包括3名患者的双侧斗室开放。

主要结果测量包括局灶性纹状体BBB开放的安全性和可行性。运动和认知功能、磁共振成像(MRI)、18F-氟多巴(FDOPA)和β-淀粉样蛋白PET(正电子发射断层成像)图像的变化被确定。

他们发现:该手术是可行的,耐受性良好,没有严重的不良事件。在随访中没有发现运动和认知(神经心理学测试)功能方面的神经相关变化。

MRI显示,治疗后不久(24小时至14天),壳核BBB关闭,排除了出血性和缺血性病变。目标区域的β-淀粉样蛋白摄取量有不连续但明显的减少,FDOPA PET没有变化。这些初步结果表明,FUS介导的纹状体BBB开放是可行和安全的,因此可以成为一种有效的工具,以促进PD中推定的神经恢复性分子的传递。

原文出处:
Pineda‐Pardo JA, Gasca‐Salas C, Fernández‐Rodríguez B, et al. Striatal Blood–Brain Barrier Opening in Parkinson’s Disease Dementia: A Pilot Exploratory Study. _Movement Disorders_. Published online June 28, 2022:mds.29134. doi:[10.1002/mds.29134](https://doi.org/10.1002/mds.29134)

评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-12-07 cmj8wellington

    #Dis#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-11-30 anminleiryan

    #ERS#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2023-02-18 cmsvly

    #Disord#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-12 zhangying8788
  8. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 ms6000000960504356

    不错的文章

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2077709, encodeId=cb1820e7709f1, content=<a href='/topic/show?id=67cc600242' target=_blank style='color:#2F92EE;'>#disorder#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=171, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6002, encryptionId=67cc600242, topicName=disorder)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fc52500170, createdName=12498cbcm00(暂无昵称), createdTime=Sat Oct 22 01:07:40 CST 2022, time=2022-10-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1820125, encodeId=2f521820125c4, content=<a href='/topic/show?id=d5ad1003015d' target=_blank style='color:#2F92EE;'>#预防帕金森#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=131, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100301, encryptionId=d5ad1003015d, topicName=预防帕金森)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Dec 29 18:07:40 CST 2022, time=2022-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2013920, encodeId=ad1a2013920ae, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=185, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Dec 07 03:07:40 CST 2022, time=2022-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878556, encodeId=87ce18e8556a5, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=176, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Wed Nov 30 14:07:40 CST 2022, time=2022-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784526, encodeId=63b11e84526eb, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=136, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Sat Feb 18 19:07:40 CST 2023, time=2023-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1738141, encodeId=83df1e38141d0, content=<a href='/topic/show?id=e10b600329' target=_blank style='color:#2F92EE;'>#disorders#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=152, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6003, encryptionId=e10b600329, topicName=disorders)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=efbf34357637, createdName=ms2186806800017884, createdTime=Sat Oct 08 03:07:40 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262394, encodeId=e4491262394c1, content=<a href='/topic/show?id=ff3c89946de' target=_blank style='color:#2F92EE;'>#血脑屏障#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=164, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89946, encryptionId=ff3c89946de, topicName=血脑屏障)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68b666, createdName=zhangying8788, createdTime=Tue Jul 12 15:07:40 CST 2022, time=2022-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231750, encodeId=44511231e5075, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a><a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=181, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛), TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:15 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1231749, encodeId=3db51231e4959, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0825417521, createdName=ms6000000960504356, createdTime=Mon Jul 11 11:07:04 CST 2022, time=2022-07-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1247136, encodeId=5ad9124e136b6, content=老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!, beContent=null, objectType=article, channel=null, level=null, likeNumber=161, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=neuro.Dr, createdTime=Mon Jul 11 03:07:40 CST 2022, time=2022-07-11, status=1, ipAttribution=)]
    2022-07-11 neuro.Dr

    老年性痴呆,未来还是希望借助神经电生理吧,也许更为有效!

    0

相关资讯

Movement disorders:帕金森氏征,多巴胺代谢和大脑血流代谢有何关系?

在PD和四次重复的tauopathy中,前额叶灌注与同侧黑质多巴胺能功能有关

Movement disorders:帕金森病:黑质中的铁沉积,如何随时间变化?

在开始使用多巴胺能药物治疗之前,黑质铁较低,然后在整个疾病过程中不断增加,直到晚期达到平稳

Cell:徐浩新/胡美钦/李平/王策等揭示帕金森病发病风险的新机制

该研究开辟了溶酶体 pH 调节的新方向,首次鉴定出溶酶体膜上的氢离子通道:TMEM175 是一种新型的氢离子激活的氢离子通道。

Movement disorders-帕金森病伴肌张力障碍与否,皮层和下丘脑有何改变?

运动皮层和STN场电位的频谱功率在重复肢体运动时有明显的不同。

Movement disorders:帕金森患者,糖尿病可加速其进展

T2DM与帕金森病的疾病进展速度有关,突出了这两种疾病之间的互动。

Movement disorders 同济大学;帕金森病:短链脂肪酸减少,或因肠-血屏障受损

PD患者的粪便和血浆SCFAs的改变与GBB受损有关,并可能因便秘而加重。

拓展阅读

帕金森病核心病理难追踪?【Cell】曹鹏团队给α-Syn聚集体装上“荧光追踪器”

本研究开发的α-Syn可视化报告系统可实现:检测α-Syn聚集体对神经元活动的影响;评估其诱导的神经元病理改变;标记不同类型神经元中的α-Syn聚集体;筛选抑制α-Syn包涵体形成的化合物。

南京邮电大学汪联辉/王婷ACS Nano:开发鼻内共形贴片,实现帕金森病持续给药与活性氧清除

本研究首次构建了鼻内共形贴片CuLC/SNF,通过“湿度响应黏附-持续释放-ROS清除”三位一体的创新策略,实现了帕金森病的高效治疗。

EBioMedicine:帕金森病循环神经相关蛋白的遗传-蛋白质组-临床综合研究

本研究通过遗传和蛋白质组学整合,鉴定了59种与帕金森病相关的神经相关蛋白,揭示了潜在的致病机制和治疗靶点,并通过临床病例对照验证了部分蛋白的诊断价值。

Lancet子刊:帕金森病不“一刀切”,男女发病特征、风险因素差异显著

该研究全面揭示了澳大利亚PD患者的临床及流行病学特征,强调了性别差异在PD发病及进展中的重要性,为PD的性别特异性研究、临床护理及公共卫生策略制定提供了坚实的数据支撑。

Nutrients综述:植物化学物质调控氧化应激,为阿尔茨海默病与帕金森病患者神经保护筑牢依据

发表于Nutrients杂志的一项综述梳理了植物化学物质在AD和PD中的治疗潜力,揭示了通过调控氧化应激这一共同核心病理环节,为开发新一代神经保护策略提供了坚实依据。

Lancet子刊:荷兰帕金森病发病率及空间分布的全国性研究(2017–2022年)

本研究利用多源健康数据,首次全面评估了荷兰2017至2022年帕金森病(PD)发病率及其空间分布,发现发病率总体稳定但存在明显地区差异,且无法用已知环境因素完全解释。

NEJM综述:帕金森病(2024)

暂未更新 · 2024-08-01